Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2020

View Archived Issues

Targeted delivery improves checkpoint blockade

A potent and selective allosteric inhibitor of SHP2 that overcomes tumor resistance to osimertinib

Carcinogens need not be mutagens

Lantern Pharma and Georgetown University advance development of LP-184

New JAK inhibitors identified at Beijing Scitech-Mq Pharmaceuticals

Patient screening ongoing in phase IIa study of IP-2018

NervGen provides updates regarding development of NVG-291

First-in-human data for the anti-BCMA antibody-drug conjugate AMG-224

Hangzhou Innogate Pharma discovers ALK/mutant EGFR/MAP4K1 inhibitors

Kyushu University presents new lysosomal alpha-glucosidase inhibitors

Central China Normal University synthesizes new TRK inhibitors

Three win Nobel Prize for hepatitis C discoveries

NuvoBio patents N-lysine methyltransferase KMT5A inhibitors

Pralsetinib shows promising activity in RET-mutant MTC in the phase I/II ARROW trial

PALLAS: palbociclib not beneficial in early breast cancer treated with endocrine therapy

miRagen to discontinue internal development of cobomarsen for CTCL

NMD Pharma begins phase I/IIa trial of NMD-670 to treat symptoms of myasthenia gravis

Santhera ends development of idebenone following phase III futility analysis

Phase I data for LXH-254 plus LTT-462 in patients with KRAS- or BRAF-mutant NSCLC

Clinical results reported for anti-TIGIT antibody vibostolimab +/- pembrolizumab in NSCLC

FDA approves Opdivo + Yervoy for unresectable malignant pleural mesothelioma

Promising data seen in phase I studies of bispecific HER2/4-1BB molecule PRS-343

Tarsius reports phase I/II data on TRS-01 in active noninfectious anterior uveitis

Kodiak Sciences begins pivotal studies of KSI-301 in DME and RVO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...